No connection

Search Results

RKDA

BEARISH
$1.18 Live
Arcadia Biosciences, Inc. · NASDAQ
$0.9 52W Range $6.71

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$2.43M
P/E
N/A
ROE
-45.1%
Profit margin
-48.1%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.

Key Strengths

Strong short-term liquidity (Current Ratio: 3.09)
Positive Gross Margin (36.04%) indicating product viability
Low Price-to-Book ratio (0.39) suggesting deep discount to assets
Low Price-to-Sales ratio (0.50)
Recent quarterly EPS surprises have been volatile but occasionally positive

Key Risks

Critical fundamental health (Piotroski F-Score: 0/9)
Severe operational losses (Operating Margin: -152.61%)
Negative revenue growth (-25.90% YoY)
Extreme long-term capital erosion (-98.8% 5-year change)
Complete lack of analyst coverage and institutional support
AI Fair Value Estimate
Based on comprehensive analysis
$0.85
-28.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
12
Weak
Value
30
Future
10
Past
5
Health
15
Dividend
0
AI Verdict
Distressed / High Risk
Key drivers: 0/9 Piotroski Score, Negative Revenue Growth, Extreme Operating Losses, Severe Price Depreciation
Confidence
90%
Value
30/100

Trades at a deep discount to book value, but this is typical for companies in financial distress.

Positives
  • P/B of 0.39
  • P/S of 0.50
Watchpoints
  • No Graham Number available
  • Negative earnings make P/E irrelevant
Future
10/100

Growth metrics are negative and the business model is shrinking.

Positives
  • Recent Q/Q EPS growth spike
Watchpoints
  • Revenue growth is -25.90%
  • No clear path to profitability
Past
5/100

Historical price performance is catastrophic.

Positives
  • Occasional earnings beats
Watchpoints
  • 5Y Change: -98.8%
  • 1Y Change: -60.0%
Health
15/100

Liquidity is the only positive; operational health is non-existent.

Positives
  • Current Ratio 3.09
  • Quick Ratio 2.42
Watchpoints
  • Piotroski F-Score 0/9
  • ROE -45.14%
Dividend
0/100

Company is not in a position to return capital.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.18

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RKDA and closest competitors.

Updated 2026-04-17
RKD
Arcadia Biosciences, Inc.
Primary
5Y
-98.8%
3Y
-83.0%
1Y
-60.0%
6M
-78.5%
1M
-24.4%
1W
-10.6%
IBG
Innovation Beverage Group Limited
Peer
5Y
-98.5%
3Y
-98.5%
1Y
-93.3%
6M
-92.9%
1M
-53.1%
1W
-7.8%
KID
Classover Holdings, Inc.
Peer
5Y
-98.8%
3Y
-98.8%
1Y
-97.5%
6M
-95.3%
1M
-16.0%
1W
-31.4%
GNL
Greenlane Holdings, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.8%
6M
-91.2%
1M
-58.4%
1W
+2.9%
PAV
Paranovus Entertainment Technology Ltd.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.9%
6M
-99.8%
1M
-56.5%
1W
-12.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.92
PEG Ratio
N/A
P/B Ratio
0.39
P/S Ratio
0.5
EV/Revenue
-0.44
EV/EBITDA
0.41
Market Cap
$2.43M

Profitability

Profit margins and return metrics

Profit Margin -48.15%
Operating Margin -152.61%
Gross Margin 36.04%
ROE -45.14%
ROA -32.71%

Growth

Revenue and earnings growth rates

Revenue Growth -25.9%
Earnings Growth N/A
Q/Q Revenue Growth -25.9%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
3.09
Strong
Quick Ratio
2.42
Excellent
Cash/Share
$2.22

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
21.3%
Op. Margin
-152.6%
Net Margin
-148.3%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.58x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-19
$N/A
2025-11-07
$0.62
+214.8% surprise
2025-08-14
$-3.26
-312.7% surprise
2025-05-08
$1.9
+293.9% surprise

Consumer Defensive Sector Comparison

Comparing RKDA against 108 companies in the Consumer Defensive sector (6 bullish, 44 neutral, 58 bearish)
Return on Equity (ROE)
-45.14%
This Stock
vs
-21.08%
Sector Avg
+114.2% (Excellent)
Profit Margin
-48.15%
This Stock
vs
-6.85%
Sector Avg
+602.7% (Superior)
Revenue Growth
-25.9%
This Stock
vs
172.71%
Sector Avg
-115.0% (Slower)
Current Ratio
3.09
This Stock
vs
2.32
Sector Avg
+33.2% (Stronger)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-03

Recursion Pharmaceuticals filed an 8-K on April 3, 2026, likely to announce its first-quarter financial results or a material corporate development.

10-K
10-K
2026-03-26

RKDA filed its 10-K annual report on March 26, 2026, which includes standard disclosures regarding its business operations, risk factors, and financial condition. While the filing contains detailed sections for management's discussion and analysis, specific financial highlights and risk metrics were not provided in the available excerpts.

8-K
8-K
2026-03-26
8-K
8-K
2026-02-06
8-K
8-K
2026-01-14

Recursion Pharmaceuticals filed an 8-K on January 14, 2026, likely to disclose a material corporate update or clinical pipeline development.

8-K
8-K
2025-12-29
8-K
8-K
2025-12-23
DEF 14A
DEF 14A
2025-11-19

RKDA filed a definitive proxy statement on November 19, 2025, providing shareholders with the necessary information to vote on corporate matters at an upcoming meeting.

10-Q
10-Q
2025-11-07

RKDA filed its quarterly 10-Q report on November 7, 2025. The filing includes a section dedicated to risk factors under Item 1A, although specific financial highlights and detailed risk disclosures were not provided in the available excerpts.

8-K
8-K
2025-11-07

Recursion Pharmaceuticals likely reported its third-quarter financial results in this 8-K filing.

8-K
8-K
2025-10-24
8-K
8-K
2025-08-29
8-K
8-K
2025-08-14
10-Q
10-Q
2025-08-14
8-K
8-K
2025-05-16
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning RKDA from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile